ArticleCell death and differentiation2026
Targeting the USP7-PRMT6 epigenetic axis overcomes chemoresistance in breast cancer by coordinating H3R2me2a deposition and RNF168 methylation for DNA repair and ferroptosis blockade.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging roles of USP7 in tumor immune evasion, metabolic reprogramming, and therapeutic resistance.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Platinum resistance in breast cancer remains a major therapeutic challenge due to convergent escape mechanisms. Here, we identify the PRMT6/USP7 complex as a dual epigenetic orchestrator of chemoresistance. Mechanistically, USP7-mediated deubiquitination of H2BK120ub facilitates PRMT6-dependent deposition of the repressive mark H3R2me2a, concomitant with the exclusion of activating H3K4me3. This coordinated histone crosstalk reprograms the chromatin landscape, leading to transcriptional silencing of the ferroptosis regulator TAZ (WWTR1). Consequently, TAZ suppression disrupts lipid peroxidation and blocks cisplatin-induced ferroptosis, a critical cell death pathway. Simultaneously, the PRMT6/USP7 complex recruits the E3 ubiquitin ligase RNF168 to sites of DNA damage, promoting H2AX monoubiquitination and robust activation of both homologous recombination (HR) and non-homologous end-joining (NHEJ) repair pathways, thereby enhancing DNA damage tolerance. To translate this mechanism, we engineered an injectable hydrogel for the sequential co-delivery of cisplatin and PRMT6/USP7 inhibitors, demonstrating significantly enhanced therapeutic efficacy. Our study unveils a previously unrecognized bifunctional role for the PRMT6-USP7 axis in orchestrating epigenetic reprogramming and DNA repair to confer platinum resistance, providing profound mechanistic insights and a compelling co-targeting strategy for overcoming chemoresistance in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.